# A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer

> **NCT05945927** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 178 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab emtansine

## Key facts

- **NCT ID:** NCT05945927
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-13
- **Primary completion:** 2025-08-30
- **Final completion:** 2025-08-30
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2025-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05945927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05945927, "A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05945927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*